Safety and Tolerability of Deucravacitinib in Patients With Moderate to Severe Plaque Psoriasis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)
J Eur Acad Dermatol Venereol 2024 Mar 07;[EPub Ahead of Print], B Strober, A Blauvelt, RB Warren, KA Papp, AW Armstrong, KB Gordon, A Morita, AF Alexis, M Lebwohl, P Foley, RM Kisa, E Colston, T Wang, S Banerjee, D ThaçiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.